Study of tumor neuroendocrin origin
Conditions
Interventions
Product Name: GA68-DOTANOC
Pharmaceutical Form: Solution for injection
INN or Proposed INN: 68 Ga-Dotanoc
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 185-
Sponsors
AZIENDA U.L.S.S. N.8 DI ASOLO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult subjects (male and female) with recent diagnosis of neuroendocrine tumors (such as carcinoid and GEP tumors) before treatment. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Normal volunteers, young people, pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): Compare the percentage of patients identified with positive CT scan showing the percentage of patients identified themselves with positive PET;Main Objective: To assess the role of 68Ga-DOTANOC PET in the diagnosis of neuroendocrine tumors, respect to other imaging modalities, particularly CT, comparing the percentage of patients identified with positive CT scan showing the percentage of patients identified themselves with positive PET;Secondary Objective: To highlight, in patients diagnosed with blood chemistry (determination of chromogranin positivity) and / or clinic, the number of lesions identified on CT than the number of injuries ``active`` positive PET with 68Ga-DOTANOC and therefore expressing somatostatin receptors. | — |
Countries
Italy
Outcome results
None listed